Skin boosters (microdroplet hyaluronic acid)

Also known as: Skinvive, Profhilo, VYC-12, skin quality injectables, biorevitalization, microdroplet HA

Skin boosters are lightly cross-linked or hybrid hyaluronic acid gels injected in tiny droplets across the skin surface, aiming to hydrate and smooth from within rather than fill any specific line. Skinvive by Juvederm became the first FDA-approved product in this class in May 2023, for cheek smoothness, backed by a randomized evaluator-blind trial. Profhilo, popular internationally, has a 2026 systematic review of 9 studies behind it, though mostly without control groups. These deliver measurable but subtle changes in hydration and surface smoothness, not lift or wrinkle correction.

How it works

Instead of a bolus of firm gel placed deep, skin boosters spread many microdroplets of soft HA into the upper skin layers. The HA binds water, raising skin hydration measurably, and may nudge fibroblasts toward collagen and elastin production. Profhilo uses thermally bonded high and low molecular weight HA that spreads through tissue from 5 injection points per side; Skinvive uses small cross-linked droplets across the cheek.

What the evidence says, claim by claim

These are the results measured in studies, not the results shown in ads. Where the research is weak, the grade says so.

For dullness and texture

Moderate evidence

In the randomized evaluator-blind trial behind Skinvive's FDA approval, VYC-12L significantly improved cheek smoothness, fine lines, and hydration versus control. An earlier prospective study found 96.2 percent of patients were smoothness responders at month 1 and 76.3 percent at month 4, with skin hydration significantly improved through month 9. Effects are real but modest and centered on hydration and surface quality.

Randomized trials support this use, but they are few, small, or short. The effect is probably real. The size of it is less certain.

A Randomized, Multicenter, Evaluator-blind Study to Evaluate the Safety and Effectiveness of VYC-12L Treatment for Skin Quality Improvements (Dermatologic Surgery, 2023; RCT)
VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study (Clinical, Cosmetic and Investigational Dermatology, 2019; cohort)

For skin laxity

Limited evidence

Profhilo is marketed heavily for laxity of the face, neck, and body. A 2026 systematic review of 9 studies with 278 participants reported improvements in laxity, elasticity, hydration, and density, but the included studies were mostly small, open-label, and lacked placebo controls, and Profhilo is not FDA approved in the US. Treat firmness claims as plausible but unproven at the controlled-trial level.

Only small, short, or lower-quality studies exist. Treat marketing claims about this use with caution.

A Systematic Review of the Efficacy and Safety of Profhilo and Profhilo Body (Plastic and Aesthetic Nursing, 2026; systematic-review)

For wrinkles and fine lines

Limited evidence

Skin boosters soften fine surface lines as a byproduct of hydration; the VYC-12L randomized trial included fine lines among improved endpoints. They do not lift folds or treat expression lines, and anyone with moderate to deep wrinkles will get clearly more from botulinum toxin or conventional filler. For fine crepey lines the effect is genuine but small and temporary.

Only small, short, or lower-quality studies exist. Treat marketing claims about this use with caution.

A Randomized, Multicenter, Evaluator-blind Study to Evaluate the Safety and Effectiveness of VYC-12L Treatment for Skin Quality Improvements (Dermatologic Surgery, 2023; RCT)

Risks and what can go wrong

Side effects are the mildest of any injectable filler class: redness, small bumps at injection points, bruising, and swelling, typically resolving in 1 to 7 days. Trial adverse events for VYC-12 were all mild to moderate. Because product is placed superficially in many sites, visible papules that take days to settle are the most common complaint. Standard filler contraindications apply: active skin infection, pregnancy (unstudied), and known HA hypersensitivity. Vascular risk is lower than with deep bolus filler but not zero.

The practical details

Skinvive typically runs 600 to 900 dollars per session in the US, with results lasting about 6 months; the label supports repeat treatment. Profhilo, where available outside the US, is usually sold as 2 sessions 4 weeks apart with maintenance every 6 months. Skinvive is FDA approved for improving cheek smoothness in adults over 21; Profhilo and most other skin boosters are not FDA approved and their US use is off-label or unavailable.